Florian Brand is the CEO of ATAI Life Sciences N.V., a company focused on biotechnology. Born in 1979, he co-founded ATAI in 2018 and has led the company through important developments in mental health treatments. Brand's background includes being the...

Florian Brand is the CEO of ATAI Life Sciences N.V., a company focused on biotechnology. Born in 1979, he co-founded ATAI in 2018 and has led the company through important developments in mental health treatments. Brand's background includes being the Managing Director at Springlane GmbH before founding ATAI. Over the years, he has seen his compensation fluctuate significantly, with a peak total compensation of around $26 million in 2021 when many of his stock options vested following the company's successful IPO. By 2023, his total compensation dropped to about $792,000, which illustrates the impacts of company performance on executive pay. Brand holds a substantial share of the company, owning around 6.8% directly and more through a unique Hurdle Share Option Program that benefits his financial interests greatly during successful exits or liquidity events. Interesting to note, he has been engaged in substantial insider trading activities in relation to ATAI, showcasing a belief in the company's potential as he offloads shares and options periodically. By June 2024, he will step down as CEO but continue supporting the company's transition, indicating a structured approach to leadership changes and continuity in vision.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other ATAI Life Sciences N.V. CEOs

A

Florian Brand

Founder and Ex-CEO of ATAI Life Sciences N.V.

Education

Not specified

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1979 - 46 years ago

CEO of ATAI Life Sciences N.V. for

3 years 11 months (Jan 2021 - Dec 2024)

Previous Experience

Various leadership positions in biotechnology companies, including Kalyra Pharmaceuticals and Avelas Biosciences.

Rivals

Competitors/colleagues of Florian Brand

Holdings

See how much did Florian Brand make over time.

Florian Brand holds approximately 6.8% of ATAI Life Sciences, a significant stake in the company. His holdings peaked with the vesting of 4.2 million HSOP shares in 2022, which boosted his wealth immensely as some of these shares are tied...

Florian Brand holds approximately 6.8% of ATAI Life Sciences, a significant stake in the company. His holdings peaked with the vesting of 4.2 million HSOP shares in 2022, which boosted his wealth immensely as some of these shares are tied to exit events. In total, he has an estimated control over 11.3 million shares when combining direct ownership and options. Between 2021 and 2024, his insider trading showed fluctuations in share sales, where in March 2023 alone, he sold over $119,000 in shares, indicating an active engagement in managing his stake. He has leveraged his options effectively, particularly when the company has met its performance goals. This shows Brand's strategic foresight in the company’s projected success over the years.

Total Stock Sold

$281.42K

ATAI

$281.42K

151,303 ATAI shares

What if they kept their stock?

If Florian Brand didn't sell their stock, today they would have:
Extra ATAI151,303 shares worth $2.94M.
This is 945.7% and $2.66M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Florian Brand.

ATAI

$290.50K

ATAI at $1.92/share

May 16, 2024

Sale

ATAI

$23.12K

ATAI at $1.16/share

Nov 16, 2023

Purchase

ATAI

$57.97K

ATAI at $1.45/share

Sep 13, 2023

Purchase

ATAI

$103.56K

ATAI at $1.48/share

Mar 29, 2023

Purchase

ATAI

$35.00K

ATAI at $15.00/share

Jun 22, 2021

Purchase

Compensation History

See how much did Florian Brand make over time.

Florian Brand's compensation has varied significantly through his tenure as CEO of ATAI Life Sciences. In 2023, he received a total of $792,325, including a base salary of $550,000 and performance-based bonuses that were paid at 85% of their target due to achieving corporate goals. His highest earning year was 2021, when he earned over $26 million, largely due to the vesting of planned stock options that came with his position. In contrast, in 2022, his total pay was around $4.25 million, which included a substantial portion from stock option grants. This highlights how performance metrics affect pay, demonstrating the company's strategy to align executive compensation with success and stockholder value creation. The overall compensation plan shows a focus on retention and performance alignment within the company.

Year

2023

Total Compensation

$793.33K

Salary

$550.00K

Board Justification

The executive compensation program is designed to align executive pay with performance, linking it to stockholder value creation and retention strategies.

Bonus

$233.75K

Board Justification

Performance-based annual cash bonuses for the named executive officers for fiscal year 2023, paid at 85% of their target bonus opportunities due to achieving 85% of corporate goals.

Other

$9.58K

Board Justification

Includes contributions to a German pension scheme and private insurance premiums.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2023 as the amounts reflect only stock options and restricted stock units granted, not vested.

Performance Metrics

The 2023 bonuses were based on corporate, clinical, and financing goals.

Other ATAI Life Sciences N.V. CEOs

Here are other CEOs of ATAI Life Sciences N.V.

Srinivas Rao

Founder and CEO of ATAI Life Sciences N.V.

June 2024 - Present